Treatments
553 articles
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
A New Combination Chemotherapy Before Surgery
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
A Report from ASCO GI 2022
Clinical trials were reported on at ASCO GI 2022, as well as reports on COVID, virtual tumor boards, and racial disparities in treatment.
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Testing the Addition of a New Drug to Radiation Therapy for Localized Pancreatic Cancer
In combination with radiation treatment, researchers are testing a new drug that causes DNA damage to make that treatment more effective.
Making Surgery An Option for More Pancreatic Cancer Patients
Dr. John Chabot explains that more pancreatic cancer patients may qualify for surgery if they consult an experience pancreatic surgical team.
New Phase III Clinical Trial Actively Recruiting
Dr. Zev Wainberg is enthusiastic about the phase III clinical trial combining a new drug and standard chemo to make immunotherapy more effective.
Chemotherapy Plus Immunotherapy Trial Shows Promise
Dr. Gulam Manji leads a clinical trial that uses two types of immunotherapy to enhance chemotherapy for pancreatic cancer patients.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE) makes it easier for chemotherapy to reach pancreatic cancer cells.
Immunotherapy to Help Shrink Pancreatic Tumors for Surgery
Researchers are looking at adding checkpoint drugs–a type of immunotherapy–to standard chemoradiation to shrink pancreatic cancer for surgery.
New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.